[1]
Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (London, England). 2006 Aug 5:368(9534):489-504
[PubMed PMID: 16890836]
[2]
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12:316(2):191-210. doi: 10.1001/jama.2016.8900. Epub
[PubMed PMID: 27404187]
[3]
Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS currents. 2010 Dec 7:2():RRN1203. doi: 10.1371/currents.RRN1203. Epub 2010 Dec 7
[PubMed PMID: 21151380]
[4]
Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. The AIDS reader. 2001 Apr:11(4):222-6
[PubMed PMID: 11392679]
Level 3 (low-level) evidence
[5]
Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, Miles JJ, Kjer-Nielsen L, Gras S, Williamson NA, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012 Jun 28:486(7404):554-8. doi: 10.1038/nature11147. Epub
[PubMed PMID: 22722860]
[6]
Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (London, England). 2005 Jun 10:19(9):979-81
[PubMed PMID: 15905681]
[7]
Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. AIDS (London, England). 2008 May 31:22(9):999-1007. doi: 10.1097/QAD.0b013e3282f7cb60. Epub
[PubMed PMID: 18520343]
[8]
Martin MA, Kroetz DL. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy. 2013 Jul:33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3
[PubMed PMID: 23649914]
[9]
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M, Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Apr 1:46(7):1111-8. doi: 10.1086/529382. Epub
[PubMed PMID: 18444831]
[10]
Phillips EJ, Mallal SA. Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. The Journal of clinical investigation. 2018 Jul 2:128(7):2746-2749. doi: 10.1172/JCI121525. Epub 2018 May 21
[PubMed PMID: 29781810]
[11]
Cardone M, Garcia K, Tilahun ME, Boyd LF, Gebreyohannes S, Yano M, Roderiquez G, Akue AD, Juengst L, Mattson E, Ananthula S, Natarajan K, Puig M, Margulies DH, Norcross MA. A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. The Journal of clinical investigation. 2018 Jul 2:128(7):2819-2832. doi: 10.1172/JCI99321. Epub 2018 May 21
[PubMed PMID: 29782330]
[12]
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. The New England journal of medicine. 2008 Feb 7:358(6):568-79. doi: 10.1056/NEJMoa0706135. Epub
[PubMed PMID: 18256392]
[13]
Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE. Abacavir hypersensitivity reaction: an update. The Annals of pharmacotherapy. 2008 Mar:42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26
[PubMed PMID: 18303141]